A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

Phase 2 Completed 52 enrolled Janssen Research & Development, LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate on-treatment efficacy against hepatitis D virus (HDV) of JNJ-73763989 + nucleos(t)ide analog (NA) regimen compared to NA alone.

Timeline

Start: 2020-09-17
Primary completion: 2023-10-19
Completion: 2025-03-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JNJ-73763989	Small interfering RNA (siRNA)	—	Subcutaneous
Background	Entecavir	Small molecule	—	Oral
Background	Tenofovir disoproxil fumarate	Small molecule	—	Oral
Background	tenofovir alafenamide	Small molecule	—	Oral

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

Summary

Timeline

Drugs

Indications